Identification of Palmitoleic Acid Controlled by mTOR Signaling as a Biomarker of Polymyositis

Abstract EN

Polymyositis (PM) is a chronic disease characterized by muscle pain, weakness, and increase in muscle-related enzymes, accompanied with inflammations in lymphocytes.

However, it is not well understood how the molecular alternations in lymphocytes contribute to the development of polymyositis.

The mechanistic target of rapamycin (mTOR) signaling is the central regulator of metabolism and inflammation in mammalian cells.

Based on previous studies, we proposed that mTOR signaling may control inflammatory reactions via lipid metabolism.

In this study, we aim to figure out the role of mTOR signaling in the development of polymyositis and identify novel biomarkers for the detection and therapy of polymyositis.

After screening and validation, we found that palmitoleic acid, a monounsaturated fatty acid, is highly regulated by mTOR signaling.

Inhibition of mTORC1 activity decreases palmitoleic acid level.

Moreover, mTORC1 regulates the level of palmitoleic acid by controlling its de novo synthesis.

Importantly, increased palmitoleic acid has been proven to be a marker of polymyositis.

Our work identifies palmitoleic acid in peripheral blood mononuclear cells (PBMC) as a biomarker of polymyositis and offers new targets to the clinical therapy.